Dr Davies speaks with ecancertv at ASH 2016 about phase III trials of obinutuzumab, an anti-CD20 monoclonal antibody for the treatment of follicular lymphoma.

He describes the influence of pre-treatment on tolerability, and draws comparison to rituximab based chemotherapy for efficacy, but notes concerns over toxicity management.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.